Trial Profile
FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PETRARCA; PETRARCA/FLOT 6
- 16 Jun 2022 Results assessing the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2-positive resectable EGA published in the Journal of Clinical Oncology
- 21 Sep 2020 Final results and sub-group analysis, presented at the 45th European Society for Medical Oncology Congress.
- 31 May 2020 Primary endpoint (PhaseII: Rate of pathological complete response) has been met as per result presented at the 56th Annual Meeting of the American Society of Clinical Oncology